Emilie Voltz

861 total citations
7 papers, 676 citations indexed

About

Emilie Voltz is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Emilie Voltz has authored 7 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 2 papers in Immunology and 2 papers in Cancer Research. Recurrent topics in Emilie Voltz's work include interferon and immune responses (2 papers), Histone Deacetylase Inhibitors Research (2 papers) and Protein Degradation and Inhibitors (2 papers). Emilie Voltz is often cited by papers focused on interferon and immune responses (2 papers), Histone Deacetylase Inhibitors Research (2 papers) and Protein Degradation and Inhibitors (2 papers). Emilie Voltz collaborates with scholars based in France, United States and Switzerland. Emilie Voltz's co-authors include Hinrich Gronemeyer, Nicole Clarke, Francesco Bresciani, Ángel R. de Lera, Paola Bontempo, Lucia Altucci, Ettore Mariano Schiavone, Rosana Álvarez, Alessandro Weisz and Emmanuelle Germain and has published in prestigious journals such as Nature Medicine, The EMBO Journal and The International Journal of Biochemistry & Cell Biology.

In The Last Decade

Emilie Voltz

7 papers receiving 669 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emilie Voltz France	6	576	141	115	82	77	7	676
Angelika Rosenauer Canada	11	654 1.1×	135 1.0×	57 0.5×	219 2.7×	108 1.4×	12	786
Keli Song United States	10	336 0.6×	105 0.7×	120 1.0×	38 0.5×	37 0.5×	19	475
Karl J. Mathis United States	10	303 0.5×	71 0.5×	78 0.7×	44 0.5×	63 0.8×	17	509
Xuejia Yang China	7	764 1.3×	50 0.4×	152 1.3×	27 0.3×	68 0.9×	10	859
Jayasha Shandilya India	17	658 1.1×	35 0.2×	139 1.2×	45 0.5×	56 0.7×	27	814
Jeff Lightfoot Canada	10	728 1.3×	119 0.8×	141 1.2×	52 0.6×	150 1.9×	15	925
Roberto Dal Zuffo Italy	11	636 1.1×	60 0.4×	105 0.9×	69 0.8×	43 0.6×	13	770
Lior Golomb Israel	11	726 1.3×	89 0.6×	242 2.1×	49 0.6×	52 0.7×	14	924
Ding-Yen Lin Taiwan	11	702 1.2×	102 0.7×	170 1.5×	30 0.4×	138 1.8×	15	854
Oscar W. Huang United States	8	566 1.0×	41 0.3×	144 1.3×	37 0.5×	66 0.9×	8	614

Countries citing papers authored by Emilie Voltz

Since Specialization

Citations

This map shows the geographic impact of Emilie Voltz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilie Voltz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilie Voltz more than expected).

Fields of papers citing papers by Emilie Voltz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilie Voltz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilie Voltz. The network helps show where Emilie Voltz may publish in the future.

Co-authorship network of co-authors of Emilie Voltz

This figure shows the co-authorship network connecting the top 25 collaborators of Emilie Voltz. A scholar is included among the top collaborators of Emilie Voltz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilie Voltz. Emilie Voltz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Voltz, Emilie, Ülrike Sommer, Elaine Tritto, et al.. (2024). First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor. Clinical and Translational Science. 17(5). e13789–e13789. 27 indexed citations

2.

Charnas, Lawrence, Emilie Voltz, A. Hartmann, et al.. (2017). Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results. Neuromuscular Disorders. 27. S207–S208. 18 indexed citations

3.

Ufer, Mike, Alexandros Sagkriotis, Ganesan Subramanian, et al.. (2016). Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056). Clinical Therapeutics. 38(12). 2589–2597. 2 indexed citations

4.

Lund, Per, Irina Kotova, Valérie Kedinger, et al.. (2011). Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine. Molecular Cancer Therapeutics. 10(9). 1611–1623. 16 indexed citations

5.

Voltz, Emilie & Hinrich Gronemeyer. (2007). A new era of cancer therapy: Cancer cell targeted therapies are coming of age. The International Journal of Biochemistry & Cell Biology. 40(1). 1–8. 12 indexed citations

6.

Clarke, Nicole, Ana M. Jiménez‐Lara, Emilie Voltz, & Hinrich Gronemeyer. (2004). Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. The EMBO Journal. 23(15). 3051–3060. 115 indexed citations

7.

Nebbioso, Angela, Nicole Clarke, Emilie Voltz, et al.. (2004). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine. 11(1). 77–84. 486 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact